The Umeå based life science company InfiCure Bio continues to take large
steps in the global market by signing agreements with two major
international companies.
“The contracts with our new clients clearly show that pharmaceutical
companies continue to invest in the development of new drugs for fibrosis,
which is extremely promising for InfiCure Bio”, says InfiCure Bio’s CEO, Sofia
Mayans.
Read the full pressrelease here
